Whipplewood Advisors’s RxSight RXST Stock Holding History

Whipplewood Advisors’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-179	Closed	-$328	–	1258
2025 Q1	$328	Buy	179 +166	+1,277%	+$4.93K	﹤0.01%	1165
2024 Q4	$447	Buy	+13	New	+$586	﹤0.01%	1127

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NSGL

No Street GP LP San Francisco, California $1.5B AUM 34.53% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Whipplewood Advisors's RXST Position: Q2 2025 in Review

Whipplewood Advisors sold out of RxSight (RXST) in Q2 2025, closing a stake of 179 shares — an estimated $328 sold.

Whipplewood Advisors first reported a position in RXST in Q4 2024 and held it in 2 quarters. The position peaked at $447 in Q4 2024. 174 funds tracked by Wall St. Rank hold RXST as of Q2 2025.

Whipplewood Advisors reported no remaining RxSight position as of Q2 2025 after selling out during the quarter.
Whipplewood Advisors sold 179 RxSight shares in Q2 2025, an estimated $328.
Whipplewood Advisors first reported a position in RxSight in Q4 2024 and held it in 2 quarters.
Whipplewood Advisors's RxSight position peaked at $447 in Q4 2024.
174 funds tracked by Wall St. Rank held RxSight as of Q2 2025.

Based on Whipplewood Advisors's 13F filing for Q2 2025, filed 31 Jul 2025.